Advance notification letters increase adherence in colorectal cancer screening: A population-based randomized trial

被引:50
作者
van Roan, A. H. C. [1 ]
Hal, L. [1 ]
Wilschut, J. A.
Reijerink, J. C. I. Y. [2 ]
van Vuuren, A. J. [1 ]
van Ballegooijen, M.
Habbema, J. D. F.
van Leerdam, M. E. [1 ]
Kuipers, Ernst J. [1 ]
机构
[1] Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, NL-3015 CE Rotterdam, Netherlands
[2] Assoc Nationwide Screening SW Netherlands, NL-3134 ZB Vlaardingen, Netherlands
关键词
Colorectal cancer screening; Advance notification letter; Adherence; Population-based; Randomized trial; PARTICIPATION;
D O I
10.1016/j.ypmed.2011.01.032
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective. The population benefit of screening depends not only on the effectiveness of the test, but also on adherence, which, for colorectal cancer (CRC) screening remains low. An advance notification letter may increase adherence, however, no population-based randomized trials have been conducted to provide evidence of this. Method. In 2008, a representative sample of the Dutch population (aged 50-74 years) was randomized. All 2493 invitees in group A were sent an advance notification letter, followed two weeks later by a standard invitation. The 2507 invitees in group B only received the standard invitation. Non-respondents in both groups were sent a reminder 6 weeks after the invitation. Results. The advance notification letters resulted in a significantly higher adherence (64.4% versus 61.1%, p-value 0.019). Multivariate logistic regression analysis showed no significant interactions between group and age, sex, or socio-economic status. Cost analysis showed that the incremental cost per additional detected advanced neoplasia due to sending an advance notification letter was (sic)957. Conclusion. This population-based randomized trial demonstrates that sending an advance notification letter significantly increases adherence by 3.3%. The incremental cost per additional detected advanced neoplasia is acceptable. We therefore recommend that such letters are incorporated within the standard CRC-screening invitation process. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 19 条
[1]  
[Anonymous], 2010, Cancer Facts Figures 2010
[2]  
BASTOS J, 2009, INT J CANC
[3]   An advance notification letter increases participation in colorectal cancer screening [J].
Cole, S. R. ;
Smith, A. ;
Wilson, C. ;
Turnbull, D. ;
Esterman, A. ;
Young, G. P. .
JOURNAL OF MEDICAL SCREENING, 2007, 14 (02) :73-75
[4]   The staging of colorectal cancer: 2004 and beyond [J].
Compton, CC ;
Greene, FL .
CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (06) :295-308
[5]  
HARDCASTLE JD, 1986, CANCER-AM CANCER SOC, V58, P397, DOI 10.1002/1097-0142(19860715)58:2<397::AID-CNCR2820580235>3.0.CO
[6]  
2-X
[7]   Screening for colorectal cancer using the faecal occult blood test, Hemoccult [J].
Hewitson, P. ;
Glasziou, P. ;
Irwig, L. ;
Towler, B. ;
Watson, E. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01)
[8]   Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: A randomized, controlled trial [J].
Hoffman, Richard M. ;
Steel, Susan ;
Yee, Ellen F. T. ;
Massie, Larry ;
Schrader, Ronald M. ;
Murata, Glen H. .
PREVENTIVE MEDICINE, 2010, 50 (5-6) :297-299
[9]   Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy [J].
Hol, L. ;
van Leerdam, M. E. ;
van Ballegooijen, M. ;
van Vuuren, A. J. ;
van Dekken, H. ;
Reijerink, J. C. I. Y. ;
van der Togt, A. C. M. ;
Habbema, J. D. F. ;
Kuipers, E. J. .
GUT, 2010, 59 (01) :62-68
[10]   Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels [J].
Hol, L. ;
Wilschut, J. A. ;
van Ballegooijen, M. ;
van Vuuren, A. J. ;
van der Valk, H. ;
Reijerink, J. C. I. Y. ;
van der Togt, Acm ;
Kuipers, E. J. ;
Habbema, J. D. F. ;
van Leerdam, Me .
BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1103-1110